CAN, with optimal therapy (ACEI/ARB, β-blockers) in patients with metabolic syndrome, stabilized HF with reduced EF, protects deterioration of myocardial mechano-energetic efficiency, improves diastolic dysfunction and maximizes the decrease in BNP. This evidence concerns the gene NPPB and hydrops fetalis.